Cannabis Bioscience Nanoparticle Breast Cancer Treatment
Summary
Cannabis Bioscience International Holdings Inc has filed patent application US20260108536A1 for a cannabinoid-based nanoplatform composition targeting breast cancer treatment. The composition incorporates phytocannabinoids (THC, CBD, CBG, CBC) into nanoparticles smaller than 200 nm using nano-emulsification techniques for enhanced bioavailability and controlled release. The treatment targets ER+, PR+, HER2-positive, and triple-negative breast cancers at stages I and II by inhibiting VEGF pathways and inducing apoptosis.
“Aspects of the disclosure relate to a composition and methods for treating breast cancer using a cannabinoid-based nanoplatform.”
About this source
USPTO classification A61K covers pharmaceutical preparations: formulations, dosage forms, combination therapies, delivery systems, and the vehicles that carry active ingredients. Every newly published application in A61K lands in this feed, around 245 a month. Applications publish 18 months after filing, so this feed reveals what pharma formulators at major sponsors and generics were working on in the prior year and a half. Watch this if you compete in drug formulation, file freedom-to-operate analyses, scout competitive drug products before clinical readouts, or follow novel delivery platforms like nanoparticles, lipid carriers, and long-acting injectables.
What changed
Cannabis Bioscience International Holdings Inc has filed USPTO patent application US20260108536A1 disclosing a novel cannabinoid-based nanoparticle composition for breast cancer treatment. The application claims a composition comprising THC, CBD, CBG, and CBC incorporated into nanoparticles smaller than 200 nm, produced via nano-emulsification techniques for enhanced bioavailability and controlled release. The method of treatment involves administering the composition to breast cancer patients at stages I and II to inhibit VEGF pathways and induce apoptosis across ER+, PR+, HER2-positive, and triple-negative breast cancer subtypes.
Pharmaceutical and biotechnology companies developing cannabinoid-based therapeutics or nanoparticle drug delivery systems should monitor this filing for competitive intelligence purposes. The patent's broad claims across multiple phytocannabinoid combinations and breast cancer subtypes may affect freedom-to-operate considerations for similar therapeutic approaches.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Cannabinoid based nanoplatform composition and methods for treating breast cancer by inhibiting VEGF
Application US20260108536A1 Kind: A1 Apr 23, 2026
Assignee
Cannabis Bioscience International Holdings Inc
Inventors
Rosangel del Valle Andrades Fuentes, Nancy Paola Duarte Delgado, Nancy Rodrigues Das Fontes, Stephanie Dona Hartmann, Ana Maria Maldonado Vacca
Abstract
Aspects of the disclosure relate to a composition and methods for treating breast cancer using a cannabinoid-based nanoplatform. The composition comprises phytocannabinoids, including THC, CBD, CBG, and CBC, incorporated into nanoparticles for enhanced bioavailability and controlled release. The method involves administering the composition to patients with breast cancer, particularly stages I and II, to inhibit VEGF pathways and induce apoptosis. The treatment targets estrogen receptor-positive (ER+), progesterone receptor-positive (PR+), HER2-positive, and triple-negative breast cancers. Aspects of the disclosure further provide the production of the composition using nano emulsification techniques to create nanoparticles smaller than 200 nm. This composition offers a novel, targeted approach to reducing tumor growth and metastasis in breast cancer patients.
CPC Classifications
A61K 31/658 A61K 9/1075 A61K 9/4825 A61K 9/4858 A61K 9/4866 A61K 47/10
Filing Date
2024-10-17
Application No.
18918386
Mentioned entities
Parties
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.